| Cat.No. | Name | Information |
|---|---|---|
| M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| M1974 | Roscovitine | Roscovitine (Seliciclib) is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5, with IC50 values of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively. |
| M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
| M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
| M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
| M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
| M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
| M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
| M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
| M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
| M9755 | CYC065 | CYC065 (Fadraciclib) is an orally bioavailable inhibitor of cyclin dependent kinases 2 and 9 (CDK2/9) with IC50 values of 5 and 26 nM, respectively. |
| M9622 | BAY-1143572 Racemate | BAY-1143572 Racemate (Atuveciclib Racemate) is the racemate mixture of Atuveciclib, Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM. |
| M9558 | JSH-150 | JSH-150 is a potent CDK9 inhibitor with IC50 of 1 nM. |
| M9553 | PF-06873600 | PF-06873600 is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. |
| M9489 | SY-1365 | SY-1365 (Mevociclib) is a potent, first-in-class, selective CDK7 inhibitor with a Ki value of 17.4 nM.Mevociclib exhibits antiproliferative and apoptotic activity in solid tumor cell lines. |
| M8995 | THZ2 | THZ2 (an analog of THZ1) is a potent and selective CDK7 inhibitor which overcomes the instability of THZ1 in vivo (IC50s: CDK7=13.9 nM; TNBC cells=10 nM). |
| M8969 | LY-3177833 | LY-3177833 is a potent and selective inhibitor of CDC7 with IC50 of 3.3 nM. |
| M8962 | Voruciclib | Voruciclib (P1446A-05) is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with IC50s of 90nM, 25nM, and 22nM for CDK4-CyclinD1, CDK1-Cyclin B, and CDK9-Cyclin T, respectively. |
| M8902 | CVT-313 | CVT-313 is a potent and selective inhibitor of CDK2 that prevents neointimal proliferation, which has an IC50 of 0.5 microM in vitro. |
| M8497 | NU6140 | NU6140 is a CDK2 inhibitor with 10-36-fold selectivity over other CDK family members. |
| M8369 | PNU112455A hydrochloride | PNU112455A is an ATP site competetive inhibitor of CDK2 and CDK5. |
| M8015 | Purvalanol A | Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor. |
| M7557 | ON123300 | ON123300 is a potent inhibitor of CDK4, with an IC50 of 3.8 nM, with little inhibitory activity against CDKs 1,2,5 and 8. |
| M6589 | CGP 60474 | CGP60474 is a highly effective anti-endotoxin compound, It is an effective cyclin-dependent kinase (CDK) inhibitor (IC50 of CDK1/B, CDK2/E, CDK2/ A, CDK4/D, CDK5/ P25, CDK7/H and CDK9/T are 26, 3, 4, 216, 10, 200 and 13 nM, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor. |
| M6283 | SCH 900776 (CAS:891494-64-7) | MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. |
| M6199 | MSC2530818 | MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable. |
| M6160 | Bohemine | Bohemine is A selective CDK inhibitor with IC50 of 4.6 μM, 83 μM and 2.7 μM against Cdk2/ Cyclin E, Cdk2/ Cyclin A and Cdk9/cyclin T1, respectively. Bohemine also inhibited ERK2, IC50 was 52 μM, and inhibited CDK1, CDK4 and CDK6. Bohemine is also a purine analogue and has a wide range of anticancer activities. |
| M5332 | NU2058 | NU2058 is a guanine-based CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1. |
| M5328 | LDC000067 | LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7. |
| M5263 | LDC4297 | LDC4297 is a novel CDK7 inhibitor (IC50=0.13±0.06 nM for CDK7 versus IC50s between 10 nM and 10,000 nM for all other analyzed CDKs). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
